| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lakewood-Amedex Biotherapeutics Inc.$2.43
-0.25 (-9.81%)
D 33Pipeline Score Fair Value Biotech · Clinical
Market Cap
9.91 M
EPS
-0.88
P/E Ratio
-
Value Trade
150.01 K
-64.31 %
Week
-91.17 %
1 Month
-91.17 %
3 Month
-91.17 %
6 Month
-91.17 %
5 Year
-91.17 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
983.11 K
52 Week Range
0.69 - 9.82
% held by Insiders
0 %
% held by Institutions
-
Enterprise Value
11.65 M
Total Shares
14.02 M
Short %
2.16 %
Float Shares
6.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lakewood-Amedex Biotherapeutics Inc.
1Total events
1Upcoming
0Tier-1 (high impact)
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D33
Pipeline Score $16M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.6x
rNPV / MCap Top 41%
Micro Cap (rank 539 of 912)
Percentile RankLakewood-Amedex Biotherapeutics Inc. faces pipeline headwinds (33/100), with $1.3B risk-adjusted pipeline value, led by Antimicrobial agent in Diabetic Foot Ulcers (DFUs) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antimicrobial agent Small molecule | Diabetic Foot Ulcers (DFUs) | Phase 2 | NCT07565506 | 43% | $558M | NOT YET_RECRUITING | 24 | - | C (53) | Dec 1, 2026 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Nu-3 | mildly infected diabetic foot ulcers | Phase 2 | 2026-05-27 | Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Read More | Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers Read More | |
Nu-3 | mildly infected diabetic foot ulcers | Phase 2 | 2026-05-27 | Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Read More | Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers Read More | |
Nu-3 | mildly infected diabetic foot ulcers | Phase 2 | 2026-05-27 | Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Read More | Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LABT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LABT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LABT▼ -9.8%today
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics announced promising preclinical safety data for its Nu-3 gel, aimed at treating infected diabetic foot ulcers. The data supports the selection of doses for an upcoming Phase 2a trial, showing that Nu-3 was well-tolerated and did not inhibit wound healing. The company is preparing to initiate the trial with selected concentrations of the gel.
Read more →LABT▼ -12.8%on this news
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics has expressed support for the reintroduction of the PASTEUR Act, aimed at combating antimicrobial resistance (AMR). The company highlights its Bisphosphocin® platform and lead candidate Nu-3, which targets infected diabetic foot ulcers. This initiative is crucial as AMR poses a significant threat to global healthcare.
Read more →LABT▼ -7.8%on this news
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has appointed Dr. David G. Armstrong as Study Chair for its Phase 2a trial of Nu-3, targeting infected diabetic foot ulcers. Dr. Armstrong, a leading expert in diabetic foot care, will also serve as a Scientific Advisor for the iDFU program. The trial will assess the safety and efficacy of three concentrations of Nu-3 gel, aiming to fill a critical gap in treatment options for this patient population.
Read more →LABT▼ -5.5%on this newsshared move
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Lakewood-Amedex Biotherapeutics has secured a new patent in Australia for its Bisphosphocin® compounds aimed at treating various antimicrobial infections. This patent adds to the company's extensive intellectual property portfolio, which includes 72 granted patents globally. The CEO emphasized the importance of these innovations in combating antimicrobial resistance, a significant global health crisis.
Read more →LABTLakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Lakewood-Amedex Biotherapeutics Inc. will present at the Life Sciences Virtual Investor Forum on June 25, 2026. CEO Kelvin Cooper will discuss the company's growth strategy and its lead candidate, Nu-3, a topical gel for infected diabetic foot ulcers. The company aims to address a significant patient population with this innovative treatment as it moves into Phase 2 clinical trials.
Read more →LABTLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has expanded its global intellectual property portfolio by issuing two new patents for its lead candidate, Nu-3, aimed at treating mildly infected diabetic foot ulcers. The company now holds 71 granted patents and 28 pending applications, enhancing its competitive stance in the antimicrobial market. The gel formulation of Nu-3 is set to enter Phase 2 clinical trials.
Read more →LABT▼ -36.7%on this news· ran to -49% by day 3
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has announced positive data for its lead candidate, Nu-3, which is advancing towards a Phase 2 clinical trial for treating mildly infected diabetic foot ulcers. The company has successfully completed key formulation and manufacturing processes, demonstrating stability and effectiveness against antibiotic-resistant bacteria. The planned Phase 2 trial aims to further assess the safety and efficacy of Nu-3.
Read more →LABT▲ +6.3%on this news
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing
Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, following its recent direct listing on Nasdaq. Dr. Tucker, a veteran biotech executive, brings over two decades of experience which is expected to strengthen the company’s governance and strategic capabilities. His insights are anticipated to be valuable as Lakewood-Amedex focuses on advancing its growth strategy and developing its lead product, Nu-3, aimed at treating diabetic foot ulcers amid concerns of antibiotic resistance.
Read more →Competitive Position
How LABT ranks across every disease it competes inCompetitive Position is a premium feature
See how LABT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial